Paper39589586
Advances in irreversible electroporation for prostate cancer.
Liu X and 9 others. Discov Oncol, 2024. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Advances in irreversible electroporation for prostate cancer. Papers, record 39589586. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39589586
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2023YFC2413403 | National Key Research and Development Program of China | PubMed | ||
| 82004110 | National Natural Science Foundation of China | PubMed | ||
| K2023041 | Key project of Jiangsu Provincial Health Commission | PubMed | ||
| MS2023081 | General Program State Administration of Traditional Chinese Medicine of Jiangsu | PubMed |
Source PubMed
References123
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36216618 | Impact of margin accentuation with intraoperative irreversible electroporation on local recurrence in resected pancreatic cancer. | Surgery | 2023 | https://conductscience.org/library/papers/36216618 | PubMed |
| 2 | 27393627 | Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma. | J Surg Oncol | 2016 | https://conductscience.org/library/papers/27393627 | PubMed |
| 3 | 36901812 | Irreversible Electroporation in Pancreatic Cancer-An Evolving Experimental and Clinical Method. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36901812 | PubMed |
| 4 | 36073928 | Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years. | J Urol | 2023 | https://conductscience.org/library/papers/36073928 | PubMed |
| 5 | 32488359 | Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE). | World J Urol | 2021 | https://conductscience.org/library/papers/32488359 | PubMed |
| 6 | 30986263 | Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments. | PLoS One | 2019 | https://conductscience.org/library/papers/30986263 | PubMed |
| 7 | 29075594 | Irreversible electroporation of stage 3 locally advanced pancreatic cancer: optimal technique and outcomes. | J Vis Surg | 2015 | https://conductscience.org/library/papers/29075594 | PubMed |
| 8 | 35044426 | Experimental and Numerical Investigation of Parameters Affecting High-Frequency Irreversible Electroporation for Prostate Cancer Ablation. | J Biomech Eng | 2022 | https://conductscience.org/library/papers/35044426 | PubMed |
| 9 | 39080139 | Irreversible Electroporation Margin Accentuation in Pancreaticoduodenectomy: A Propensity Score Matching Analysis. | Ann Surg Oncol | 2024 | https://conductscience.org/library/papers/39080139 | PubMed |
| 10 | 29594551 | Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. | World J Urol | 2018 | https://conductscience.org/library/papers/29594551 | PubMed |
| 11 | 31069281 | An evaluation of irreversible electroporation thresholds in human prostate cancer and potential correlations to physiological measurements. | APL Bioeng | 2017 | https://conductscience.org/library/papers/31069281 | PubMed |
| 12 | 29102671 | Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation. | Eur Urol Focus | 2019 | https://conductscience.org/library/papers/29102671 | PubMed |
| 13 | 38513683 | MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial. | Lancet Gastroenterol Hepatol | 2024 | https://conductscience.org/library/papers/38513683 | PubMed |
| 14 | 35793110 | Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial. | JAMA Surg | 2022 | https://conductscience.org/library/papers/35793110 | PubMed |
| 15 | 31971335 | Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. | BJU Int | 2020 | https://conductscience.org/library/papers/31971335 | PubMed |
| 16 | 32423258 | Mathematical modeling of the thermal effects of irreversible electroporation for in vitro, in vivo, and clinical use: a systematic review. | Int J Hyperthermia | 2020 | https://conductscience.org/library/papers/32423258 | PubMed |
| 17 | 31161973 | Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes. | Radiology | 2019 | https://conductscience.org/library/papers/31161973 | PubMed |
| 18 | 24589913 | Comparison of the effects of the repetition rate between microsecond and nanosecond pulses: electropermeabilization-induced electro-desensitization? | Biochim Biophys Acta | 2014 | https://conductscience.org/library/papers/24589913 | PubMed |
| 19 | 36687122 | Irreversible electroporation for the management of pancreatic cancer: Current data and future directions. | World J Gastroenterol | 2023 | https://conductscience.org/library/papers/36687122 | PubMed |
| 20 | 34349171 | Effects of high-frequency nanosecond pulses on prostate cancer cells. | Sci Rep | 2021 | https://conductscience.org/library/papers/34349171 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41908232 | Irreversible electroporation for localized prostate cancer: risk-stratified oncologic outcomes and functional preservation. | Prostate Int | 2026 | https://conductscience.org/library/papers/41908232 | PubMed |
| 41357174 | Pulsed electric fields: a sharp sword in the battle against cancers. | Front Immunol | 2025 | https://conductscience.org/library/papers/41357174 | PubMed |
| 41132360 | Optilume drug-coated balloon dilation for treatment of post-prostate cancer ablative therapy urethral stricture: a case series. | Transl Androl Urol | 2025 | https://conductscience.org/library/papers/41132360 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39589586
GET https://conductscience.org/api/papers/v1/39589586/references?page=2